Eli Lilly and Co. employees knew the Alzheimer's treatment solanezumab was not a sure bet. But that didn't make the pain any less acute after the company announced the drug had failed to demonstrate effectiveness during a 2,100-patient Phase 3 clinical trial.
In Lilly’s partnership with Harvard Pilgrim Health Care, the not-for-profit insurer gets additional rebates if fewer patients using Lilly's diabetes treatment Trulicity meet blood sugar goals than expected.
Indianapolis-based Anthem Inc. on Wednesday won a court ruling blocking Cigna Corp. from terminating a proposed merger between the health insurers until a judge could weigh arguments over the faltering deal at an April 10 hearing.
Merck & Co. on Tuesday announced that it will end a study of its once-promising Alzheimer’s disease drug in patients with mild-to-moderate forms of the condition, just three months after Eli Lilly and Co. announced its own setback in a field that’s been littered with failures.
The collapse of one potential mega-merger and the uncertain future of the other could hurt shoppers on the Affordable Care Act exchanges next year by leaving them with even fewer options and potentially higher prices.
A review by The Associated Press found Seema Verma and her small Indianapolis-based firm made millions through consulting agreements with at least nine states while also working under contract for Hewlett Packard.